First Colorectal Cancer Patient Receives LB-100 in LIXTE-NKI Clinical Trial Backed by Major Pharma

Aug. 26, 2024 -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company") has initiated a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and F. Hoffmann-La Roche Ltd. ("Roche") to treat unresponsive (MSI Low) metastatic colorectal cancer.

This clinical trial (NCT06012734, clinicaltrials.gov) involves LIXTE providing its leading compound, LB-100, while Roche supplies atezolizumab (Tecentriq ®, a PDL1 inhibitor) through the imCORE Network. The imCORE Network is a global academic-industry partnership aimed at accelerating cancer immunotherapy research via institution-sponsored studies.

Dr. Neeltje Steeghs, a medical oncologist at NKI, highlighted the goal of the trial: "Our objective with this trial is to bring immunotherapy as an effective treatment option to approximately 85 percent of all colorectal cancer patients, who thus far have not been responsive to traditional protocols."

Bas van der Baan, Chief Executive Officer of LIXTE, expressed satisfaction with the commencement of this crucial trial, which is funded by Roche. He noted, "This is the second recent clinical trial combining LB-100 with immunotherapy that is funded by a major pharmaceutical company, following the start of a clinical trial earlier this year with GSK for treating clear cell ovarian cancer."

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company that focuses on identifying new targets for cancer drug development and creating therapies for commercialization. The company's lead clinical PP2A inhibitor, LB-100, has been shown to be well-tolerated in cancer patients at doses that exhibit anti-cancer activity. Extensive published preclinical data (available at www.lixte.com) suggest that LB-100 has the potential to significantly enhance the efficacy of chemotherapies and immunotherapies, thereby improving patient outcomes.

LB-100 is part of a groundbreaking initiative in a novel area of cancer biology known as activation lethality, which is contributing to a new treatment paradigm. LIXTE's innovative approach is protected by a comprehensive patent portfolio. Currently, proof-of-concept clinical trials are underway for colorectal, ovarian, and sarcoma cancers. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!